61219-76-9
61219-76-9
Chemical Structure
DL-Mevalonolactone-d3
Synonym(s): (±)-Mevalonolactone-d3;Mevalolactone-d3
- CAS No.: 61219-76-9
- Formula:C6H7D3O3
- Molecular Weight:133.16
IUPAC Name: 4-hydroxy-4-(methyl-d3)tetrahydro-2H-pyran-2-one
InChIKey: JYVXNLLUYHCIIH-FIBGUPNXSA-N
SMILES: O=C1CC(C([2H])([2H])[2H])(O)CCO1
Biological Activity: DL-Mevalonolactone-d3 is the deuterium labeled DL-Mevalonolactone[1]. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling[2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DL-Mevalonolactone-d3 | DL-Mevalonolactone-d3 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone (Standard) | ≥98% | DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-13C2 | DL-Mevalonolactone-13C2 ((±)-Mevalonolactone-13C2) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-13C | DL-Mevalonolactone-13C ((±)-Mevalonolactone-13C) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-d7 | 99.27% | DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-d4 | DL-Mevalonolactone-d4 ( (±)-Mevalonolactone-d4) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone | 99.15% | DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Domingos SR, et al. On the structural intricacies of a metabolic precursor: Direct spectroscopic detection of water-induced conformational reshaping of mevalonolactone. J Chem Phys. 2017 Sep 28;147(12):124310. [Content Brief]
- [3]. Cecatto C, et al. Mevalonolactone disrupts mitochondrial functions and induces permeability transition pore opening in rat brain mitochondria: Implications for the pathogenesis of mevalonic aciduria. Neurochem Int. 2017 Sep108:133-145. [Content Brief]
